Healthcare Equipment and Supplies
Company Overview of Singulex, Inc.
Singulex, Inc. develops and manufactures immunodiagnostic products. It provides immunoassay systems, which includes benchtop analytical instrumentation, integrated and prepared reagents for ultrasensitive immunoassays, and software to automatically analyze data and display detailed assay reports. The company also offers molecule counting products; ultrasensitive immunoassays, such as inflammation, cardiovascular, neurology, oncology, metabolism, and toxicity; SgxHD for cardiovascular monitoring; and custom services and support, such as sample testing, assay development, and antibody derivatization. Singulex, Inc. was formerly known as BioProfile Corporation and changed its name to Singulex, ...
1650 Harbor Bay Parkway
Alameda, CA 94502
Founded in 1997
Key Executives for Singulex, Inc.
Chief Financial Officer and Principal Accounting Officer
Chief Commercial Officer and Senior Vice President of Sales & Marketing
Vice President of Business Development
Compensation as of Fiscal Year 2013.
Singulex, Inc. Key Developments
Singulex, Inc. Presents at 25th Annual Piper Jaffray Healthcare Conference 2013, Dec-04-2013 11:10 AM
Dec 2 13
Singulex, Inc. Presents at 25th Annual Piper Jaffray Healthcare Conference 2013, Dec-04-2013 11:10 AM. Venue: The New York Palace Hotel, 455 Madison Avenue, New York, NY 10022, United States. Speakers: Guido Baechler, Chief Executive Officer, President and Director.
Singulex, Inc. Announces New Data of Ultrasensitive Erenna(R) Immunoassay System
Nov 19 13
Singulex, Inc. announced new data highlighting the company's ultrasensitive Erenna(R) Immunoassay System in the detection of cardiac troponin-I (cTnI). Two studies utilized the Erenna System to measure previously undetectable levels of cTnI in order to assess cardiovascular disease risk in rheumatoid arthritis (RA) and heart failure (HF) patients. The data were presented at the American Heart Association Scientific Sessions in Dallas, Texas. The research (Abstract #14247/1054, The Cardiac-Specific Troponin-I Predicts the Burden of Coronary Artery Atherosclerosis in Rheumatoid Arthritis) led by Matthew Budoff, M.D., Professor of Medicine at the David Geffen School of Medicine at UCLA and Director of Cardiac CT at Harbor-UCLA Medical Center, demonstrated that the concentration of cTnI, measured using Erenna, was directly associated with the severity of coronary artery disease in patients with RA. cTnI concentrations were found to be as predictive of coronary atherosclerosis as traditional cardiovascular tests, including coronary artery calcification (p=0.013), segmental stenosis score (p=0.024), segmental involvement score (p=0.019) and plaque burden score (p=0.029), measured via Multi-detector Computed tomography calcium scoring and non-invasive angiography. The study (Abstract #14953/5041, Serial Measurement of an Ultrasensitive Cardiac Troponin-I Predicts Cardiovascular Outcomes and Ventricular Remodeling in Chronic Heart Failure) led by James Januzzi, Jr., M.D., Director, Cardiac Intensive Care Unit at Massachusetts General Hospital, demonstrated that serial measurement of cTnI levels was able to predict future cardiac performance and risk in patients with HF. Concentrations of cTnI at baseline, 3 months and 6 months of follow-up were higher in patients with cardiovascular events than in those without (18.0 vs. 8.6 pg/mL, p = 0.003; 16.4 vs. 8.7 pg/mL, p = 0.006; 13.6 vs. 9.3 pg/mL, p = 0.03) while patients with cTnI levels less than 10.88 pg/mL were found to have a lower cardiovascular event rate (p = 0.007).
Singulex Announces Executive Changes
Oct 29 13
Singulex, Inc. announced the appointment of Jeffrey Bishop, Ph.D. as Vice President, Research and Development and Linda M. Greub as Vice President, Business Development. Dr. Bishop will oversee all R&D efforts, including assay and technology development for clinical diagnostics and life science research, as well as the addition of new content to the clinical laboratory. Ms. Greub is responsible for leading the company's partnering, licensing and merger & acquisition activities. Dr. Bishop brings extensive diagnostic industry experience to Singulex. He held a variety of leadership positions within the Research and Development organization at Alere, Inc., including recent roles as Vice President, Research and Development for specific platforms and disease areas. Ms. Greub has over 25 years of business development, strategy, investment and capital-raising experience. She joins Singulex from Novartis Diagnostics where she was Global Director of Strategy, Business Development and M&A. Ms. Greub also served as Senior Director, Strategy and Business Development at Applied Biosystems (Life Technologies) and as a senior healthcare analyst for several investment banks and hedge funds, including Banc of America Securities and Essex Investment Management.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 17, 2013